AstraZeneca PLC (NYSE:AZN) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. Deutsche Bank Maintains Sell on AstraZeneca (AZN) On March 27, 2026, Deutsche Bank maintained a Sell rating on AstraZeneca PLC (NYSE:AZN). The firm’s analyst kept a price target of £115 on the stock. On the other hand, in a more recent update, Guggenheim raised the firm’s price target on AstraZeneca PLC (NYSE:AZN) from 16,000 GBp to 16,500 GBp. Analyst Seamus Fernandez kept a Buy rating on the company’s stock. ...

AstraZeneca PLC (NASDAQ:AZN) ranks among the most undervalued NASDAQ stocks to buy now. Goldman Sachs maintained its Conviction Buy rating on AstraZeneca PLC (NASDAQ:AZN) and boosted its price target from GBP148.83 to GBP150.13 on September 16. The adjustment comes while AstraZeneca PLC (NASDAQ:AZN)  awaits the results of a Phase 3 trial for efzimfotase alfa, an enzyme replacement treatment for hypophosphatasia (HPP). Pixabay/Public Domain Goldman Sachs anticipates these findings soon, pointing out that ...